(Q36842782)

16 August 2017

1 reference

title

Targeting the PI3K-Akt pathway in kidney cancer (English)

1 reference

16 August 2017

Jin-Young Park

1

1 reference

16 August 2017

Pei-yin Lin

series ordinal

2

1 reference

16 August 2017

Robert H Weiss

series ordinal

3

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

863-870

1 reference

Kidney cancer: identification of novel targets for therapy

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Three molecularly targeted drugs tested in kidney cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Timeline: Chemotherapy and the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Structure, regulation and function of PKB/AKT--a major therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Staging laparoscopy in gastric cancer: a single port method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Loss of tumor suppressor protein PTEN during renal carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

PTEN: one gene, many syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

PI3K-Akt pathway: its functions and alterations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Structure and function of phosphoinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Sorafenib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Phosphoinositide 3-kinases as targets for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Structure-based optimization of novel azepane derivatives as PKB inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Synthesis and biological activity of Akt/PI3K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Rapamycin is an effective inhibitor of human renal cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

p21Waf1/Cip1 as a therapeutic target in breast and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

AKT Delays the Early-Activated Apoptotic Pathway in UVB-Irradiated Keratinocytes Via BAD Translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.863

21 January 2018

Identifiers

DOI

10.1586/14737140.7.6.863

1 reference

16 August 2017

1 reference